{"product_id":"slgl-pestle-analysis","title":"(SLGL) Sol-Gel Technologies Ltd. PESTLE Analysis Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePlan Smarter. Present Sharper. Compete Stronger.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Sol-Gel Technologies Ltd. PESTLE Analysis explains the political, economic, social, technological, legal, and environmental forces shaping the company and why those factors matter for strategy and investment. The page includes a real preview\/sample of the report so you can assess style and depth; purchase the full version to receive the complete ready-to-use analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePolitical factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIsrael-based headquarters in Ness Ziona\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSol-Gel Technologies Ltd.'s headquarters in Ness Ziona ties its clinical work, hiring, and partnerships to Israel's domestic policy and stability. That means shifts in government support for biotech, regulation, or security conditions can affect execution speed and investor confidence.\u003c\/p\u003e\n\u003cp\u003eBeing embedded in Israel's biotech ecosystem also helps access talent and collaborators, but it raises exposure to local political and budget priorities. If life sciences funding or approval support weakens, Sol-Gel Technologies' development momentum can slow quickly.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLife-science regulation in Israel and target markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSol-Gel Technologies Ltd. must clear Israel’s Ministry of Health plus key export regulators like the FDA and EMA before broad sales. The shift from Phase 3 data to marketing approval is where timeline risk sits, and the FDA approved 50 novel drugs in 2025, showing the bar stays high. Any filing delay can push revenue and launch timing back.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeopolitical risk in the region\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIsrael’s security risk keeps logistics fragile, and Red Sea rerouting added roughly 10-14 days to Asia-Europe shipping in 2024-2025, which can delay trial supplies and raise costs. For Sol-Gel Technologies Ltd., that uncertainty can slow study sites, strain inventory, and reduce partner confidence. Backup suppliers and inventory buffers help protect development schedules.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePublic healthcare priorities for dermatology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSkin disease is a major public health issue: the WHO says about 1.8 billion people live with skin conditions at any time, and acne, rosacea, and psoriasis keep dermatology on policy agendas. When governments push access to low-burden topical treatment, adoption can improve; for Sol-Gel Technologies Ltd., payer coverage and formulary status can still decide uptake and revenue speed.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cp\u003e1.8 billion people affected globally\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003ePolicy support favors topical medicines\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eReimbursement drives market access\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eStrategic partnership with Perrigo\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSol-Gel Technologies Ltd. partnership with Perrigo ties its pipeline to a larger commercial platform, which can reduce market-entry friction and speed access across more countries. Because Perrigo sells in regulated consumer-health channels, the alliance is more exposed to trade rules, procurement policy, and cross-border supply issues than a solo launch.\u003c\/p\u003e\n\u003cp\u003eStrategic partner strength matters here: Perrigo reported 2024 net sales of about $4.4 billion, so Sol-Gel Technologies Ltd. can benefit from a wider sales base and lower political risk if policy shifts hit one market. The trade-off is dependence on partner execution and any changes in import rules, tariffs, or healthcare channel policy.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBroader commercial reach\u003c\/li\u003e\n\u003cli\u003eLower entry friction\u003c\/li\u003e\n\u003cli\u003ePolicy and trade exposure\u003c\/li\u003e\n\u003cli\u003ePartner execution risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSol-Gel’s Growth Hinges on Israel Risk and Perrigo Reach\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSol-Gel Technologies Ltd. is exposed to Israeli policy, security, and health-regulator risk, so any shift in Ministry of Health support or wartime logistics can delay trials and approvals. The FDA approved 50 novel drugs in 2025, showing the bar stays high.\u003c\/p\u003e\n\u003cp\u003eIts Perrigo tie-up helps market reach, but also adds trade, import, and channel-policy risk. Perrigo reported about $4.4 billion in 2024 net sales.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct\" green_head blur_tbl\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003eLatest data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA novel drug approvals\u003c\/td\u003e\n\u003ctd\u003e50 in 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePerrigo net sales\u003c\/td\u003e\n\u003ctd\u003e$4.4 billion in 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eExamines how Political, Economic, Social, Technological, Environmental, and Legal forces shape Sol-Gel Technologies Ltd.’s risks and opportunities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eA concise Sol-Gel Technologies Ltd. PESTLE snapshot that quickly surfaces external risks and opportunities for easier planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a concise, traceable bibliography of industry reports, government datasets, and benchmarks to validate Sol-Gel Technologies Ltd.’s market, pricing, and competitive claims.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eEconomic factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical-stage business model\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSol-Gel Technologies Ltd. remains a clinical-stage story, so near-term revenue visibility is weak and cash burn matters more than sales. Value is tied to Phase 3 readouts and FDA approval, and biotech approval odds from first-in-human to market are often under 10%. That creates a high-risk, high-upside economic profile.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTwo Phase III assets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSol-Gel Technologies Ltd.'s Twyneo and Epsolay both completed Phase III, and that late-stage data can lift valuation and improve partnering terms. The two assets also moved into U.S. commercialization after FDA approvals in 2021 and 2022, but execution risk stays high because sales depend on reimbursement, adoption, and launch strength. In a small-cap name, even one approved product can move revenue fast, yet weak uptake can still pressure cash burn.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLower-cost topical delivery model\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSol-Gel Technologies Ltd. benefits from a lower-cost topical model because creams are easier to use than systemic drugs and can cut monitoring needs. Once-daily dosing helps adherence; in chronic dermatology, adherence often falls near 50%, so simpler use can lift sales appeal. Topical therapy also fits a large market, with psoriasis alone affecting about 125 million people worldwide.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eGeneric dermatology pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSol-Gel Technologies Ltd. uses generic topical dermatology to widen revenue beyond proprietary assets. In dermatology, generics can cut development time and cost because they rely on known active ingredients and bioequivalence, not new molecular discovery.\u003c\/p\u003e\n\u003cp\u003eThis matters for cash flow: 2025 U.S. prescription drug spending was about $435 billion, and generics filled most prescriptions at far lower prices, so even modest share can support steadier sales with lower R\u0026amp;D risk than novel drugs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDiversifies income\u003c\/li\u003e\n\u003cli\u003eShorter launch cycle\u003c\/li\u003e\n\u003cli\u003eLower scientific risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCapital intensity of R\u0026amp;D\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCapital intensity is high for Sol-Gel Technologies Ltd. because clinical trials, formulation work, and FDA filings need steady cash before sales start. In biopharma, a Phase 3 program can cost $20 million to $60 million, so late-stage work can quickly raise funding pressure. That makes partner-funded development and shared trial costs economically important.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTrials and filings need ongoing cash\u003c\/li\u003e\n\u003cli\u003eLate stage raises burn before sales\u003c\/li\u003e\n\u003cli\u003ePartner support lowers funding risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSol-Gel’s 2025 Cash Burn Hinges on Twyneo, Epsolay Uptake\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSol-Gel Technologies Ltd. faces a tight cash profile in 2025\/2026 because revenue still depends on Twyneo and Epsolay uptake, not steady product scale. Late-stage and commercial execution can move value fast, but weak reimbursement or slow adoption can keep burn high. Its generic topical line helps diversify income with lower R\u0026amp;D risk.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2025\/2026\u003c\/th\u003e\n\u003cth\u003eWhy it matters\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. prescription drug spend\u003c\/td\u003e\n\u003ctd\u003e$435B\u003c\/td\u003e\n\u003ctd\u003eLarge market, but pricing pressure is high\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiotech approval odds\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;10%\u003c\/td\u003e\n\u003ctd\u003eRaises economic risk for pipeline assets\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase 3 cost\u003c\/td\u003e\n\u003ctd\u003e$20M-$60M\u003c\/td\u003e\n\u003ctd\u003eFunding pressure stays high before sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eSol-Gel Technologies Ltd. PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact Sol-Gel Technologies Ltd. PESTLE Analysis you’ll receive after purchase—fully formatted, professionally structured, and ready to use with no placeholders or surprises.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Social-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eSociological factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh prevalence of acne and rosacea\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAcne vulgaris affects up to 85% of people ages 12 to 24, and rosacea impacts about 5% of adults worldwide. Sol-Gel Technologies Ltd.'s lead dermatology products target these two high-volume conditions, so broad patient prevalence can support recurring demand if approvals and uptake hold. In a market this large, even small penetration can translate into meaningful sales.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDemand for once-daily convenience\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSol-Gel Technologies Ltd.’s Twyneo and Epsolay are both once-daily products, and that matters because chronic dermatology patients often stick better to simpler regimens. In acne and rosacea care, convenience is a clear patient preference, so once-daily dosing can help real-world adherence and support repeat use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Social-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNon-antibiotic treatment preference\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTwyneo’s non-antibiotic profile fits a market more focused on antibiotic stewardship, as the WHO says antimicrobial resistance caused 1.27 million deaths in 2019. Patients and prescribers may prefer acne options that avoid antibiotic exposure and the resistance risk it brings. That can support uptake in acne care where long-term use is common.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eQuality-of-life impact of skin disease\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSkin disease can cut confidence and social contact; the WHO says skin conditions affect about 1.8 billion people at any time, and acne alone affects up to 85% of adolescents. That makes symptom control more than cosmetic: less redness, itching, and flares can improve daily comfort fast. Sol-Gel Technologies Ltd.'s topical pipeline can therefore create clear social value, not just clinical benefit.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cp\u003eAbout 1.8 billion people are affected worldwide.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eAcne impacts up to 85% of teens.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eTopicals can lift comfort and confidence.\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eChronic care expectations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePsoriasis affects about 125 million people worldwide, and rosacea impacts up to 5% of adults, so Sol-Gel Technologies Ltd. addresses chronic care, not one-off use. Patients need treatments that fit daily routines, which supports demand for durable, simple-to-apply gels and creams. This favors repeat use and steady adherence in long-term management.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eChronic skin diseases need routine use\u003c\/li\u003e\n\u003cli\u003eEasy-use formats improve adherence\u003c\/li\u003e\n\u003cli\u003eRepeat demand supports durable products\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-Need Skin Care, High-Value Market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSol-Gel Technologies Ltd. sells into high-prevalence skin diseases: acne affects up to 85% of ages 12 to 24, and rosacea hits about 5% of adults. Because these conditions can hurt confidence and social life, effective topical care has real social value, not just medical value.\u003c\/p\u003e\n\u003cp\u003eOnce-daily, non-antibiotic products fit patient preference for simple routines and stewardship-friendly treatment.\u003c\/p\u003e\n\u003cp\u003eThat can support adherence, repeat use, and uptake in chronic dermatology care.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcne prevalence\u003c\/td\u003e\n\u003ctd\u003eUp to 85%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRosacea prevalence\u003c\/td\u003e\n\u003ctd\u003eAbout 5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSkin disease burden\u003c\/td\u003e\n\u003ctd\u003e1.8 billion people\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Technological-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eTechnological factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProprietary microencapsulation platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSol-Gel Technologies Ltd.'s proprietary microencapsulation platform is the core of its topical drug design model, helping it control release, stability, and skin delivery. That differentiation can widen the pipeline and strengthen IP value, which matters for a small-cap company that reported $6.0 million in cash and cash equivalents at June 30, 2025. If the platform keeps producing new dermatology candidates, it can improve the odds of licensing and deal value.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOnce-daily topical formulation design\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSol-Gel Technologies Ltd. builds skin-applied medicines, and once-daily creams fit that model because they cut use from 2 doses to 1, a 50% drop in daily handling. That can help adherence, since simpler regimens tend to be used more consistently. Formulation science is the core risk and edge here: drug delivery, skin feel, and stability can make or break product performance.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Technological-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePhase III completion for Twyneo and Epsolay\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSol-Gel Technologies Ltd.'s two lead products, Twyneo and Epsolay, have both completed Phase III trials, which puts them far ahead of earlier-stage assets. That matters because Phase III success means the platform has moved beyond concept validation and into late-stage, regulatory-ready development. With 2 flagship programs already through this hurdle, Sol-Gel Technologies Ltd. shows a more mature technology base and lower clinical execution risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eEarly-stage expansion programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSol-Gel Technologies Ltd. is using early-stage expansion to spread technology risk across four dermatology programs: SGT-210 in Phase I, plus erlotinib, tapinarof, and roflumilast under investigation. That means one platform is being tested across multiple skin diseases, not just one lead asset. This setup can improve pipeline learning, but it also keeps clinical risk high until later-stage data arrive.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e4 active programs in the early pipeline\u003c\/li\u003e\n\u003cli\u003eSGT-210 is in Phase I\u003c\/li\u003e\n\u003cli\u003e3 more candidates are under investigation\u003c\/li\u003e\n\u003cli\u003ePlatform is being tested across skin diseases\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eGeneric topical development capability\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSol-Gel Technologies Ltd. shows that its know-how is not tied to novel molecules alone. With two FDA-approved topical acne drugs, EPSOLAY and TWYNEO, the Company has proved it can build and scale generic-style dermatology formulations too. That widens its technology base beyond one platform family and lowers dependence on a single product path.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTwo FDA-approved topical products\u003c\/li\u003e\n\u003cli\u003eFormulation skills beyond novel molecules\u003c\/li\u003e\n\u003cli\u003eBroader platform, lower concentration risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSol-Gel’s FDA-Backed Tech Edge, with $6M Cash on Hand\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSol-Gel Technologies Ltd.’s technology edge is its microencapsulation platform, which has already produced 2 FDA-approved products, TWYNEO and EPSOLAY, and supports once-daily topical dosing. That lowers use burden and can help adherence. The Company also had $6.0 million in cash and cash equivalents at June 30, 2025.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eKey tech factor\u003c\/th\u003e\n\u003cth\u003eLatest data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eApproved products\u003c\/td\u003e\n\u003ctd\u003e2 FDA-approved\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEarly pipeline\u003c\/td\u003e\n\u003ctd\u003e4 active programs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash at June 30, 2025\u003c\/td\u003e\n\u003ctd\u003e$6.0 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Legal-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eLegal factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical trial compliance requirements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSol-Gel Technologies Ltd. must run Phase I and Phase III studies under strict GCP rules, with regulators watching patient safety, trial conduct, and data integrity. Under ICH-GCP and FDA\/EMA oversight, any protocol breach can trigger findings, hold-ups, or rejection of results, which can slow development by months or even stop a program.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProduct approval pathways\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCommercial launch for Sol-Gel Technologies Ltd. still hinges on separate approvals in each market, and dermatology drugs must meet quality, safety, and efficacy rules before sale. In the United States, FDA review is often 10 months for standard filings and 6 months for priority review, so timing can move revenue by quarters. That makes approval speed one of the biggest legal risks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Legal-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellectual property protection\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSol-Gel Technologies Ltd. relies on patents and related rights to protect its microencapsulation platform and product formulations, which sit at the core of its commercial value. Strong IP cuts copycat and generic pressure, while weak protection can quickly erode pricing power and margins. For a small specialty pharma company, even one lost product cycle can matter.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePartnership and licensing obligations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSol-Gel Technologies Ltd.’s Perrigo alliance likely rests on detailed development and commercialization terms, including milestones, territorial rights, and revenue sharing. In a pipeline business, legal execution matters because missed obligations can delay filings, weaken cash flows, and limit value capture from licensed assets. If the contract is tight, Sol-Gel Technologies Ltd. protects upside and reduces dispute risk.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cp\u003eDefine milestones clearly.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eTrack commercialization duties.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eProtect revenue-share rights.\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eGeneric competition and exclusivity rules\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSol-Gel Technologies Ltd. competes in a generic market where timing is legal strategy: first-filer 180-day exclusivity, 5-year new-chemical-entity exclusivity, and patent suits can block launch for up to 30 months under Hatch-Waxman. Bioequivalence proof is also strict, since FDA generic approvals still hinge on the same active ingredient, dose, and route.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e180-day first-filer exclusivity can protect margins.\u003c\/li\u003e\n\u003cli\u003e5-year exclusivity can delay generic entry.\u003c\/li\u003e\n\u003cli\u003e30-month stays can shift launch timing.\u003c\/li\u003e\n\u003cli\u003ePatent cliffs decide who wins first sales.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSol-Gel Faces FDA, Patent, and Exclusivity Risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSol-Gel Technologies Ltd. faces legal risk from FDA\/EMA trial rules, since a protocol breach can delay or void data. U.S. approval timing matters too: standard review is 10 months, priority review 6 months.\u003c\/p\u003e\n\u003cp\u003eIts value also depends on patents and license terms, because Hatch-Waxman can trigger a 30-month stay, and first-filer generic exclusivity can last 180 days.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eLegal factor\u003c\/th\u003e\n\u003cth\u003eKey number\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA standard review\u003c\/td\u003e\n\u003ctd\u003e10 months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePriority review\u003c\/td\u003e\n\u003ctd\u003e6 months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHatch-Waxman stay\u003c\/td\u003e\n\u003ctd\u003e30 months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFirst-filer exclusivity\u003c\/td\u003e\n\u003ctd\u003e180 days\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Enviromental-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eEnvironmental factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharmaceutical waste handling\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTopical drug development and manufacturing create chemical, solvent, and packaging waste, so Sol-Gel Technologies Ltd. must manage hazardous streams under strict environmental rules. In the US, poor waste handling can trigger cleanup costs and penalties that can reach tens of thousands of dollars per violation per day. Tight segregation, treatment, and recycling cut contamination risk and lower operating risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSolvent and material use in formulation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMicroencapsulation and cream production need tight control of raw materials, solvents, and process inputs. The IEA said the chemicals sector emitted about 1.5 Gt of CO2 in 2023, so solvent use and emissions face rising scrutiny. For Sol-Gel Technologies Ltd., better formulation efficiency can cut waste, lower VOC releases, and reduce disposal costs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Enviromental-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEnergy use in R\u0026amp;D and manufacturing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSol-Gel Technologies Ltd. uses energy in laboratory testing, stability studies, and production, so lower power use can improve both cost control and ESG performance. In Israel, where efficient operations are under growing scrutiny, energy per batch matters more as plants and labs face tighter operating expectations. Lower energy intensity also supports sustainability goals and can reduce exposure to rising utility costs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSupply chain and logistics footprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSol-Gel Technologies Ltd. relies on regional and global supply chains to move drug substance, packaging, and finished products, so transport and warehousing add Scope 3 emissions and energy use. Partner-led distribution can lower or shift this footprint if logistics are consolidated, but it also reduces Sol-Gel Technologies Ltd.'s direct control over freight modes, storage, and return flows. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSupply chain emissions rise with air and road freight.\u003c\/li\u003e\n\u003cli\u003eWarehousing adds power, cooling, and handling impacts.\u003c\/li\u003e\n\u003cli\u003ePartner distribution can shift the footprint profile.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePressure for sustainable healthcare products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHealthcare buyers now weigh environmental impact more closely, and healthcare accounts for about 4.4% of global greenhouse-gas emissions. For Sol-Gel Technologies Ltd, dermatology products with simple, non-antibiotic profiles can fit sustainability-led buying criteria better than more complex therapies. That can support brand positioning where cleaner product stories matter.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e4.4% of global emissions\u003c\/li\u003e\n\u003cli\u003eSimple profiles aid sustainability\u003c\/li\u003e\n\u003cli\u003eBrand story can improve\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSol-Gel’s Green Risk: Solvents, Waste, and Emissions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEnvironmental risk for Sol-Gel Technologies Ltd. centers on solvent waste, VOCs, energy use, and transport emissions. The chemicals sector emitted about 1.5 Gt of CO2 in 2023, and healthcare drives about 4.4% of global emissions, so cleaner formulations and tighter batch efficiency matter. Better segregation, recycling, and lower-power lab operations can cut disposal costs and ESG risk.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003eRelevant data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eChemicals CO2\u003c\/td\u003e\n\u003ctd\u003e1.5 Gt in 2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHealthcare emissions\u003c\/td\u003e\n\u003ctd\u003e4.4% global share\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKey risk\u003c\/td\u003e\n\u003ctd\u003eSolvents, waste, freight\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234993414409,"sku":"slgl-pestle-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/slgl-pestle-analysis.webp?v=1785731793","url":"https:\/\/dcfanalyst.com\/products\/slgl-pestle-analysis","provider":"DCF Analyst","version":"1.0","type":"link"}